Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gastrointestinal Cancers
•
Medical Oncology
What is the role (if any) for MET inhibitors in advanced MET amplified gastric adenocarcinoma?
Related Questions
How would you approach a stage II colon cancer with negative ctDNA but markedly elevated CEA level post-colectomy?
Would you include HER2 directed therapy in the treatment of HER2+ small bowel adenocarcinoma?
For patients with large, partially or nearly obstructing rectal cancers, how do you sequence TNT in order to avoid complete obstruction and surgical diversion?
How would you manage a positive margin after APR for a patient who received neoadjuvant CAPOX alone due to previous remote prostate cancer radiation?
Would you use adagrasib in combination with cetuximab based on recently published article in NEJM for metastatic colon cancer with KRAS G12C mutation?
What is your preferred third-line therapy for metastatic colon cancer, RAS-WT, MSS, low TMB with no targetable alterations?
How would you approach an MSI-H HPV+ T2 N1 squamous cell carcinoma of the anus?
How would you manage a cT4N0 HER2- distal esophageal adenocarcinoma, CPS score 30, with good response to neoadjuvant chemo-RT on PET and residual disease on EGD in a patient who declines surgery?
Is there strong evidence to use TMB found in circulating tumor DNA to guide the use of ICI in metastatic colon cancer?
How do you approach patients with unresectable pancreatic cancer on gemcitabine/nab-paclitaxel-based chemotherapy q28 days with severe neutropenia?
